Skip to main navigation Skip to search Skip to main content

BIIB133: A MC, Rand, DB, PC active reference, parallel group, dose ranging Phase 2 eval effic & safety of IV Dapiirolizumab Pegol in relapsing MS

Project: Research

Project Details

StatusFinished
Effective start/end date01/1/21 → 06/1/22

Funding

  • Biogen MA Incorporated: $7,015.00